BRTX Earnings

BRTX reported its FY2025Q3 earnings on 2025-11-12, showcasing a revenue of 12.00K against an estimate of 460.00K, resulting in a -97.43% surprise. The EPS was -0.33, surpassing the expected -0.38 by 13.16% . The stock experienced a -9.42% price change on the earnings day and a -10.14% change over the next five days, reflecting market reactions to the results.

Following BRTX's FY2025Q3 earnings announcement on 2025-11-12, the stock price moved by -9.42% on the day of the release. Over the subsequent five days, it saw a -10.14% change. Historically, BRTX's stock price tends to shift by an average of +3.16% in the 10 days leading up to earnings and +6.58% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate BRTX’s annual revenue to reach 150.00K, while the EPS is projected at 0.00. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Downward by -9.26% and EPS estimates Revise Downward by -25% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between BRTX's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Downward by -9.26%, while EPS estimates moved Revise Downward by -25% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, BRTX's stock price typically moves by +3.16% in the 10 days before its earnings and +6.58% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of 0.00 and revenue of 150.00K.

The earnings call reveals significant financial challenges, including a drastic revenue decline and increased losses. The heavy dependence on clinical trials, regulatory risks, and cash burn further exacerbate concerns. Additionally, management's lack of clarity on revenue guidance and FDA timelines adds uncertainty. Despite the large market potential for BioCosmeceuticals, the absence of clear revenue projections and reliance on partnerships indicate strategic vulnerabilities. The overall sentiment from the call and Q&A is negative, suggesting a strong negative stock price reaction over the next two weeks.